That's crucial, due to the fact that the way a protein in the human body folds determines if a pharmaceutical will have the ability to bind to that protein and work. In other words, we have to understand how these proteins fold if we want a drug to work. Historically, this has been an experimental procedure (jeff brown stock predictions). However now, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it a lot easier to develop drugs that do what they're created to do. This was a breakthrough practically no one noticed. However it's going to have profound ramifications for treating disease. I predict that Alpha, Fold will be 98% accurate by the end of 2021.
And, obviously, there will be a lot of financial investment chances in this space, too. Shifting topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (korean actress). That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I would not be amazed if it pulled back maybe significantly prior to going greater - jeff brown top biotech 2020. I have actually been covering bitcoin for a long period of time now. One of the first research reports I ever published was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial suggestion, I entitled my report "What's the Big Offer With Bitcoin?" That shows you where the conversation was at the time. We were mainly educating readers. But that's not the big concern anymore. Now we're seeing institutional cash finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche business. Mass, Mutual is a trusted 170-year-old institution. So think about that. In five years, we went from informing readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake.
Which's a huge reason I'm bullish on it this year. jeff brown 1 biotech. Regards, Jeff Brown, Editor, The Bleeding Edge I have a bonus prediction 2020 was a record year for IPOs. 552 U.S. business went public the most in more than 20 years. These business raised a total of $172 billion. That's an all-time high beating the previous annual record by 43%. I predict 2021 will be another record year in IPOs. There are numerous fantastic private companies on the edge of hitting the general public markets And I have actually been dealing with a new way for you to invest even before these business go public.
This chance has been constructing over the last couple of years. I can't wait to tell you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to discover all the information. Go right here to book your spot totally free.
Emma Walsh here, handling editor of the Journal. Regular Journal readers know that tech isn't our typical beat (jeff brown biotech stock pick for 2020). And when it concerns tech investing, we leave it to the specialists. Fortunately, we have a number of such experts in our Rolodex. Our associate Jeff Brown will be familiar to our long time readers. He is among the most accomplished tech investing specialists we understand (united arab emirates). In fact, he had a number of triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to take a look at the big image and forecast what's just around the corner.
That consists of things like 5G networks, biotech, expert system, and far more. These patterns are experiencing exponential growth and producing extraordinary chances for investors. I wish to ensure all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see coming in the next 12 months Our new 5G (fifth-generation) wireless networks are a topic I have actually been covering for years now. jeff brown market predictions. But despite what numerous readers may think, this is a pattern that's just getting going. Although the COVID-19 pandemic interfered with supply chains in 2015, an impressive 250 million 5G-enabled devices were still offered.
And all of this eventually resulted in Apple postponing the release of the 5G-enabled i, Phone 12 by two months (jeff brown 2021 stock predictions). Losing two months of production and sales actually impacts how numerous 5G devices are offered in the fiscal year. When you consider all of that, offering 250 million systems is exceptional. More significantly, the hold-ups triggered by the pandemic developed a lot of bottled-up need. And that need is now going to be pushed into 2021. In fact, I forecast that more than 500 million 5G devices will be shipped in 2021 - longtime readers. And that's not my only 5G prediction When I have actually spoken about 5G in the past, I have actually described its three various phases.
In Phase Two, 5G devices go on sale. 5G phones and other products start to reach customers. And in Stage Three, 5G services start to be offered (future report). That's when we start to see applications operating on 5G networks. Think about things like massive multiplayer games over a mobile phone. That's not possible with 4G. It will be with 5G. And my second 5G prediction for 2021 is that we will start Stage Three by this summer season. This begins something of a virtuous cycle: The majority of people don't truly appreciate the technology. But they will care if there are exciting applications that can just be accessed with a 5G phone.
That leads to more 5G apps being established. In fact, 5G is going to open up a suite of incredible applications: self-driving vehicles, the Web of Things, robotic surgical treatment, and more. All of these technologies need 5G. The investment opportunities moving forward will be massive. Stepping far from 5G, the next essential technology I visualize in 2021 is CRISPR hereditary editing. CRISPR represents "clustered regularly interspaced short palindromic repeat." It's a mouthful. But it is among the most amazing advancements in biotechnology. At a high level, CRISPR is a technology that can modify our hereditary makeup as if it were software.
The program can crash or not function correctly. CRISPR utilizes a comparable concept but with our hereditary code. "Typos" in our genome can lead to illness. CRISPR can remedy these "typos." For years, CRISPR was mostly a specific niche technology that wasn't well understood. And during that time, there were actually only three companies operating in this space. However things are changing. CRISPR is no longer simply theoretical. We're seeing actual results. We're dealing with diseases and seeing that this technology just works. And as an outcome, a "second crop" of early-stage CRISPR companies is going public and providing incredible returns. This whole market is effectively a greenfield chance.
There's space for many business to exist in this area. brownstone research stock. And there will be more. That's my prediction for CRISPR in 2021. I anticipate that two or 3 more genetic editing business will hold their IPOs. Sticking to biotechnology, we are seeing fantastic things taking place at the convergence of biotech and synthetic intelligence (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its most current Alpha, Fold software application can properly predict the folding of a protein based exclusively on its amino acid series with 92. 4% accuracy. That is essential due to the fact that the way a protein in the human body folds determines if a pharmaceutical will be able to bind to that protein and be efficient.
Historically, this has been an experimental process. Today, Alpha, Fold can anticipate protein folding with 92. 4% accuracy. That's going to make it much easier to produce drugs that do what they're designed to do. And here's my next forecast. I forecast that Alpha, Fold will be 98% precise by the end of 2021. And we will see not simply one however numerous drug treatments produced utilizing this technology. This was one of those developments that almost nobody saw. But it's going to have profound implications for treating disease. And, of course, there will be plenty of financial investment opportunities in this space, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That stated, I still think bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be surprised if it drew back possibly significantly prior to going greater. I have actually been covering bitcoin for a very long time now. One of the very first research reports I ever released was on bitcoin - jeff brown top biotech stock 2021. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on investment for anybody who followed my recommendation. However at the time of that initial suggestion, I titled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But no one is asking that question any longer. Now, we're seeing institutional cash finally taking an interest in bitcoin. The big news was that Massachusetts Mutual Life Insurance took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. future report review. Mass, Mutual is a 150-year-old organization. So think about that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. Which's a huge factor why I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more benefit prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown deserves about $27. 5 million and claims the information depends on date as of February 2021, but we could not individually validate this claim. Given Jeff Brown's past, he likely has a substantial net worth, but we can't hammer down an exact figure at this moment. Brown is best known for his sage-like ability to choose winning innovation stocks. He invested more than 25 years investigating innovation business like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience offers him an exceptional viewpoint on the marketplace. He's always on the hunt for new opportunities, and he shares much of his finest choices in the Near Future Report.
That's full marks, however it's not absurdly reasoned. Brown has an exceptional track record as a stock-picker, and he successfully anticipated a few of the most significant financial occasions of the past 20 years. Although he doesn't appear to release his picks to the public, the service's success is a direct indication of Brown's stock-picking expertise. No one on Wall Street gets it ideal each time, but Jeff Brown's accurate predictions have made him legions of dedicated followers. That says a lot about his ability. The Future Report is released by Brownstone Research, a popular financial research study publisher. Brownstone Research study uses numerous research services with a variety of specializations - united states.
The company is also connected with Bonner & Partners, another well-respected research study publisher - biotech stocks jeff brown. On its site, Brownstone states its objective is to offer retail investors with professional-grade research: "For too long, the very best financial investment research study has actually not been available to private financiers. It has actually been normally booked for investment banks, hedge funds, private equity, and high-net-worth customers. jeff brown biotech pick. The mission of Brownstone Research is to make that kind of exclusive research offered to any investors wanting to gain an edge in the markets. The objective is easy to provide distinct and profitable financial investment research found no place else." -Brownstone Research study website excerpt from the Jeff Brown is the creator of Brownstone Research study, and he also functions as the company's Chief Investment Analyst.
With Brown guiding the ship, Brownstone Research is a powerhouse publisher with lots to offer its customers. After years of steady success at the helm of top-tier companies like Tesla and Area, X, Elon Musk is a household name throughout the majority of America. If you know even a bit about the market, you understand that he has a reputation as a King Midas of sorts. exponential tech investor. Everything he touches turns to gold! Jeff is well aware of Elon Musk's executive prowess, so he constantly has an eye out for the Silicon Valley rock star's next move. This time, Jeff has an early lead on Elon's next big project.
In truth, Brown believes S.A.V. exponential tech investor. could be "the most significant trend of the 2020s, and he's not alone. Take a look at these quotes from other widely known S.A.V. bulls: Elon's next huge act will be weding 2 advanced technologies: artificial intelligence and electrical cars and trucks. Musk hopes the mix will help him develop the very first fully-autonomous, self-driving cars ever. It's nothing except the automotive market's Holy Grail. As you know, electrical cars and self-driving cars and truck stocks have been big this year, however the Wall Street device has approved buzz without much concrete result. Despite an extreme boost in competition over the past few years, Brown still thinks Musk has the finest chance of putting all of it together.
tech might be the magic string that connects all of it together. S.A.V. means Shared Autonomous Car, and it could be the future of transportation. Essentially, this technology would enable you to lease out your cars and truck as a self-governing, self-driving taxi when you're not utilizing it. You simply get out of the automobile and press a button on an app that tells the cars and truck to "join the fleet." Next thing you know, you're unwinding on your sofa while your car shuttles ride-sharers around town. Best of all, you get to keep a hefty piece of the revenues. It sounds crazy, however it could be closed than you think.